136 related articles for article (PubMed ID: 27463250)
1. p53 mutations promote proteasomal activity.
Oren M; Kotler E
Nat Cell Biol; 2016 Jul; 18(8):833-5. PubMed ID: 27463250
[TBL] [Abstract][Full Text] [Related]
2. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
3. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
[TBL] [Abstract][Full Text] [Related]
4. Transcription regulation by mutant p53.
Weisz L; Oren M; Rotter V
Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 gain-of-function in cancer.
Oren M; Rotter V
Cold Spring Harb Perspect Biol; 2010 Feb; 2(2):a001107. PubMed ID: 20182618
[TBL] [Abstract][Full Text] [Related]
6. p53 and human cancers.
Lane DP
Br Med Bull; 1994 Jul; 50(3):582-99. PubMed ID: 7987642
[TBL] [Abstract][Full Text] [Related]
7. p53 mutations in cancer.
Muller PA; Vousden KH
Nat Cell Biol; 2013 Jan; 15(1):2-8. PubMed ID: 23263379
[TBL] [Abstract][Full Text] [Related]
8. p53: balancing tumour suppression and implications for the clinic.
Buganim Y; Rotter V
Eur J Cancer; 2009 Sep; 45 Suppl 1():217-34. PubMed ID: 19775621
[TBL] [Abstract][Full Text] [Related]
9. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
Monteith JA; Mellert H; Sammons MA; Kuswanto LA; Sykes SM; Resnick-Silverman L; Manfredi JJ; Berger SL; McMahon SB
Mol Oncol; 2016 Oct; 10(8):1207-20. PubMed ID: 27341992
[TBL] [Abstract][Full Text] [Related]
10. The role of mutant p53 in human cancer.
Goh AM; Coffill CR; Lane DP
J Pathol; 2011 Jan; 223(2):116-26. PubMed ID: 21125670
[TBL] [Abstract][Full Text] [Related]
11. To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo?
Workman P
Hum Exp Toxicol; 1995 Feb; 14(2):222-5. PubMed ID: 7779451
[No Abstract] [Full Text] [Related]
12. Do Mutations Turn p53 into an Oncogene?
Pitolli C; Wang Y; Mancini M; Shi Y; Melino G; Amelio I
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835684
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
14. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells.
Roger L; Jullien L; Gire V; Roux P
J Cell Sci; 2010 Apr; 123(Pt 8):1295-305. PubMed ID: 20332115
[TBL] [Abstract][Full Text] [Related]
15. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
16. p53 Mutants Access Epigenetic Pathways to Promote Tumor Growth.
Cancer Discov; 2015 Nov; 5(11):OF2. PubMed ID: 26424413
[TBL] [Abstract][Full Text] [Related]
17. Targeting mutant p53 through the mevalonate pathway.
Freed-Pastor W; Prives C
Nat Cell Biol; 2016 Oct; 18(11):1122-1124. PubMed ID: 27784901
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in p53 research: an interdisciplinary perspective.
Olivier M; Petitjean A; Marcel V; Pétré A; Mounawar M; Plymoth A; de Fromentel CC; Hainaut P
Cancer Gene Ther; 2009 Jan; 16(1):1-12. PubMed ID: 18802452
[TBL] [Abstract][Full Text] [Related]
19. p53 and its mutants on the slippery road from stemness to carcinogenesis.
Molchadsky A; Rotter V
Carcinogenesis; 2017 Apr; 38(4):347-358. PubMed ID: 28334334
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
